Europe’s science is strong. Yet, when seeing the resources allocated and cultural forces leveraged by other international giants, such as the US and China, for their economic competitiveness in life sciences, it is not uncommon for Europe to also be experienced as slow to bring innovation to market. Structural orchestration for asset framing and value-creation pathways, aligned timings and funding for maturation, or friction between sectors drivers are all parts of the knot stakeholders continuously try to disentangle moving forward. European players are not out of the game just yet. Speakers will discuss the ways Europe is already – and can further – strengthen its translation pathways to keep a competitive edge, as well as how our life sciences power can find its rightful place on the international stage, leveraging other players’ strengths for its own benefit.